Selected KEI blogs and letters on provisions in ACTA, TPP and other trade agreements on copyright damages and access to orphan works.

Selected KEI blogs and letters on provisions in ACTA, TPP and other trade agreements on copyright damages and access to orphan works. 2009 June 15, 2009, James Love, Damages, Injunctions and Transparency Key Issues in ACTA Negotiations. Available at /blogs/2009/06/15/thoughts-acta-negotiations… Continue Reading

Uncategorized

EU Trade Commissioner Backs LDC Request for TRIPS Exemption for Pharmaceuticals Until Graduation from LDC Status

In a comprehensive, 2000 word speech to the European Parliament’s International Trade Committee (INTA) on Modernising Trade Policy – Effectiveness and Responsibility, European Trade Commissioner, Cecilia Malmström, cast a wide net in her speech covering in her words, 1) the “benefits of trade for all: our economy in general, consumers, entrepreneurs, SMEs and the poorest countries”, 2) “trade policy’s commitment to our values in the world, supporting our foreign policy, promoting the respect of human rights, soci Continue Reading

Uncategorized

EU position paper (March 2015) on intellectual property flags priorities for TTIP

TrojanHorse_0.jpg

On 20 March 2015, the European Union published a position paper on intellectual property outlining its priorities for the Transatlantic Trade and Investment Partnership (TTIP). At the time of publication of this position paper, the EU noted that “the U.S. has not yet formally identified the areas of interest that it could consider as priorities.”

Continue Reading

Uncategorized

KEI intervention: TTIP Stakeholder events Round 10, Brussels (15 July 2015)

10th TTIP Stakeholder Event, Round 10
SESSION 2 Issues related to intellectual property including Geographical Indications and public health

15 July 2015

Knowledge Ecology International

A Positive Agenda for TTIP

My presentation today will address creating a positive agenda for TTIP focusing on the following six themes

1. Cooperation in funding R&D as a public good
2. Promoting the transparency of drug development costs, revenues, and prices
3. Standards for putting government funded research data and articles into free public archives
Continue Reading

Uncategorized

KEI letter to HHS, regarding 3 issues in the TPP

Attached below is a letter KEI sent to Emily Bleimund, Senior Policy Advisor for International Trade for the Department of Health and Human Services (HHS), and several other U.S. trade officials. The letter addresses three issues in the TPP text:

  1. There is a need for exceptions to exclusive rights in pharmaceutical and biologic drug test data.
  2. WTO standards for compulsory licenses should not be modified as part of a secret negotiation, or constrained by a 3-step test.
  3. Continue Reading

Uncategorized

Standing Committee on the Law of Patents (SCP) – GRULAC proposal – Revision of 1979 WIPO Model Law for Developing Countries

The World Intellectual Property Organization’s (WIPO) Twenty-Second session of the Standing Committee on the Law of Patents (SCP) will be convened from 27 July 2015 to 31 July 2015 in Geneva, Switzerland. For consideration of the Committee, the Group of Latin American and Caribbean Countries (GRULAC) have submitted a proposal entitled, Revision of 1979 WIPO Model Law for Developing Countries on Inventions (SCP/22/5). Continue Reading

July 2015: WTO reports on EU competition policy and copyright law – WTO Trade Policy Review – European Union

On 6 July 2015 and 8 July 2015, the World Trade Organization (WTO) conducted a trade policy review of the European Union. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). As noted by the WTO secretariat, the “basis for the review is a report by the WTO Secretariat and a report by the Government of the European Union” (Source: Trade Policy Review – European Union, July 2015).

Continue Reading